A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Study of Tazemetostat or Placebo with Lenalidomide plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Sponsor: Epizyme, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT0518
U.S. Govt. ID: NCT04224493
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab in patients with follicular lymphoma that has returned or has not responded to treatment (relapsed/refractory). The study will also try to select a recommended phase 3 dose of tazemetostat for further evaluation.
Investigator
Jennifer Amengual, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have follicular lymphoma? Yes No
Has your disease relapsed or progressed during/after treatment? Yes No
Are you able to take oral medication? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE